Biogen (BIIB) Cash & Current Investments (2009 - 2026)

Biogen's Cash & Current Investments history runs 18 years deep, the most recent figure standing at $4.3 billion for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 64.83% year-over-year to $4.3 billion; the TTM figure through Mar 2026 stood at $4.3 billion (up 64.83% YoY), while the FY2025 annual figure was $3.8 billion, up 60.66% from the prior year.
• Cash & Current Investments was $4.3 billion for Q1 2026 at Biogen, up from $3.8 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $6.1 billion in Q2 2023 to a low of $1.0 billion in Q4 2023.
• Historically, Cash & Current Investments has averaged $3.4 billion across 5 years, with a median of $3.8 billion in 2022.
• The sharpest annual moves came in 2024 and 2025: Cash & Current Investments plunged 78.69% in 2024, then soared 141.84% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $4.9 billion in 2022, then plunged by 78.54% to $1.0 billion in 2023, then jumped by 126.21% to $2.4 billion in 2024, then soared by 60.66% to $3.8 billion in 2025, then rose by 12.24% to $4.3 billion in 2026.
• The last three Cash & Current Investments figures came in at $4.3 billion (Q1 2026), $3.8 billion (Q4 2025), and $4.0 billion (Q3 2025), per Business Quant data.